Brief: Protagonist Therapeutics To Present Updated Phase 2 Rusfertide Clinical Results In Polycythemia Vera (Pv) At Asco 2022

Protagonist Therapeutics

27/05/2022 24:55

May 26 (Reuters) - Protagonist Therapeutics Inc  PTGX.O :
    * PROTAGONIST THERAPEUTICS TO PRESENT UPDATED PHASE 2
RUSFERTIDE
CLINICAL RESULTS IN POLYCYTHEMIA VERA (PV) AT ASCO 2022
    * PROTAGONIST THERAPEUTICS - ENROLLMENT COMPLETED AND DOSING
RESUMED IN ONGOING PHASE 2 REVIVE STUDY
    * PROTAGONIST THERAPEUTICS - RESUMPTION OF RUSFERTIDE
ADMINISTRATION AFTER SUSPENSION RESTORED THERAPEUTIC BENEFITS
INCLUDING HEMATOCRIT CONTROL
    * PROTAGONIST THERAPEUTICS - NEW DATA SHOWED TREATMENT
SUSPENSION
IN PV PATIENTS LED TO INCREASES IN HEMATOCRIT LEVELS, RBC COUNT,
AND PHLEBOTOMY RATES

Source text for Eikon:  ID:nPn6n8g2Pa 
Further company coverage:  PTGX.O 

 ((Reuters.Briefs@thomsonreuters.com;))